This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wiesner, S. M. Articles by Ohlfest, J. R. Search for Related Content PubMed PubMed Citation Articles by Wiesner, S. M. Articles by Ohlfest, J. R.

De novo Induction of Genetically Engineered Brain Tumors in Mice Using Plasmid DNA

¹ Center for Allied Health Programs, Departments of ² Pediatrics, ³ Genetics, Cell Biology, and Development, ⁴ Neurosurgery, and ⁵ Laboratory Medicine and Pathology, and ⁶ Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota

Requests for reprints: John R. Ohlfest, Department of Pediatrics, University of Minnesota, 515 Delaware Street SE, MMC 366, Minneapolis, MN 55455. Phone: 612-626-2491; Fax: 612-626-2490; E-mail: Ohlfe001{at}umn.edu.

Key Words: glioma • spontaneous mouse model • EGFRvIII • bioluminescence

Spontaneous mouse models of cancer show promise to more accurately recapitulate human disease and predict clinical efficacy. Transgenic mice or viral vectors have been required to generate spontaneous models of glioma, a lethal brain tumor, because nonviral gene transfer is typically transient. To overcome this constraint, we used the Sleeping Beauty transposable element to achieve chromosomal integration of human oncogenes into endogenous brain cells of immunocompetent mice. Genetically engineered, spontaneous brain tumors were induced with plasmid DNA in a matter of weeks in three separate mouse strains. The phenotype of tumors was influenced by the combination of oncogenes delivered, resembling human astrocytoma or glioblastoma in the majority of cases. At least five different genes can be cotransfected simultaneously including reporters, allowing measurement of tumor viability by in vivo imaging. This model can accelerate brain tumor research in a variety of ways such as generation of "humanized" models for high throughput drug screening and candidate gene validation with exceptional speed and flexibility. [Cancer Res 2009;69(2):431–9]

This article has been cited by other articles:

				E. M. C. Fisher, E. Lana-Elola, S. D. Watson, G. Vassiliou, and V. L. J. Tybulewicz New approaches for modelling sporadic genetic disease in the mouse Dis. Model. Mech., September 1, 2009; 2(9-10): 446 - 453. [Abstract] [Full Text] [PDF]